Related Experiment Video
Updated: Apr 15, 2026
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
Treatment algorithm of metastatic mucosal melanoma
1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Abstract:
Mucosal melanoma is usually considered as the most aggressive and treatment-resistant subtype of melanoma. The unsatisfactory results of standard clinical therapies for metastatic melanoma highlight the needs for effective new therapeutic strategies. Recent successes in the development of new therapies for metastatic melanoma, such as inhibitors for mitogen-activated protein kinase (MAPK) pathway and blocking antibodies against cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) or programmed cell death protein-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway, have yielded promising results, expanding the continually evolving landscape of therapeutic options for patients with this disease. In this chapter we review chemotherapies, immunotherapies, targeted therapies and angiogenesis therapies in metastatic mucosal melanoma and discuss their implications.
Insights
Mucosal melanoma, an aggressive cancer, shows poor response to standard treatments. New therapies like targeted drugs and immunotherapies offer improved outcomes for metastatic mucosal melanoma patients.
Area of Science:
- Oncology
- Dermatology
- Cancer Research
Background:
- Mucosal melanoma is recognized as a particularly aggressive and treatment-resistant form of melanoma.
- Standard therapies for metastatic melanoma have yielded unsatisfactory results, necessitating novel therapeutic approaches.
Purpose of the Study:
- To review current and emerging therapeutic strategies for metastatic mucosal melanoma.
- To discuss the implications of chemotherapies, immunotherapies, targeted therapies, and angiogenesis therapies.
Main Methods:
- Literature review of existing research on mucosal melanoma treatments.
- Analysis of recent advancements in targeted therapy (e.g., MAPK inhibitors) and immunotherapy (e.g., CTLA-4, PD-1/PD-L1 inhibitors).
Main Results:
- Recent therapeutic advancements, including targeted and immunotherapies, have shown promise for metastatic melanoma.
- These newer treatments are expanding therapeutic options for patients with this challenging disease.
Conclusions:
- Metastatic mucosal melanoma remains a difficult-to-treat cancer requiring innovative strategies.
- Chemotherapies, immunotherapies, targeted therapies, and angiogenesis therapies represent key areas of development for improving patient outcomes.
